Cargando…
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways
Histone deacetylase inhibitors (HDACi) have been evaluated in patients with Ewing sarcoma (EWS) but demonstrated limited activity. To better understand the potential for HDACi in EWS, we evaluated the combination of the HDACi vorinostat, with DNA damaging agents SN-38 (the active metabolite of irino...
Autores principales: | Sampson, Valerie B., Vetter, Nancy S., Kamara, Davida F., Collier, Anderson B., Gresh, Renee C., Kolb, E. Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646493/ https://www.ncbi.nlm.nih.gov/pubmed/26571493 http://dx.doi.org/10.1371/journal.pone.0142704 |
Ejemplares similares
-
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
por: Wang, Bi-Cheng, et al.
Publicado: (2022) -
PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma
por: Del Pozo, Vanessa, et al.
Publicado: (2021) -
A Review of Targeted Therapies Evaluated by the Pediatric Preclinical Testing Program for Osteosarcoma
por: Sampson, Valerie B., et al.
Publicado: (2013) -
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015) -
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
por: Baldwin, Paige, et al.
Publicado: (2019)